Curated News
By: NewsRamp Editorial Staff
September 28, 2026
TransCode's TTX-MC138 Shows 71% Disease Control in Phase 1a
TLDR
- TransCode's TTX-MC138 achieved 71.4% stable disease in Phase 1a, giving RNAZ a potential edge in metastatic cancer therapeutics.
- TTX-MC138 targets microRNA-10b in metastatic tumors and showed no dose-limiting toxicities at 4.8 mg/kg in 98 doses.
- TransCode's TTX-MC138 offers hope for advanced cancer patients by achieving stable disease and extended progression-free survival in early trials.
- TransCode's RNA therapy TTX-MC138 uses microRNA-10b biomarker to fight metastatic cancer with immune effects and no dose-limiting toxicities.
Impact - Why it Matters
The updated data from TransCode Therapeutics' Phase 1a trial of TTX-MC138 offer a glimmer of hope for patients with advanced solid tumors who have exhausted other treatment options. The high rate of stable disease and the absence of dose-limiting toxicities suggest that TTX-MC138 is well-tolerated and may provide clinical benefit by slowing disease progression. The GMI analysis, which showed a progression-free interval at least 30% longer than prior therapy in 40% of evaluable patients, is particularly encouraging as it indicates a potential meaningful clinical advantage over existing treatments. If these results are confirmed in larger trials, TTX-MC138 could become a valuable addition to the treatment landscape for metastatic cancers, addressing a significant unmet need. For investors, these data de-risk the program and support further development, potentially leading to partnerships or accelerated approval pathways. The immune effects observed also validate the company's RNA therapeutics approach, which could extend to other candidates in its pipeline. Overall, this news matters because it represents a step forward in the fight against hard-to-treat cancers and highlights the potential of RNA-based therapies to make a difference.
Summary
TransCode Therapeutics (NASDAQ: RNAZ) has announced promising updated clinical data from its Phase 1a trial of TTX-MC138 in patients with relapsed or refractory, unresectable locally advanced or metastatic solid tumors. As of September 1, 10 of 14 efficacy-evaluable patients (71.4%) achieved stable disease as their best overall response, with six patients progression-free at three months and three remaining progression-free at six, nine, and 12 months. The disease control rate was 57.1% at Cycle 3 Day 1 and 35.7% at Cycle 6 Day 1. A post-hoc Growth Modulation Index analysis revealed that six of 15 evaluable patients (40%) achieved a GMI greater than 1.3, indicating a progression-free interval at least 30% longer than with their immediately preceding therapy.
Safety data showed that a total of 98 doses had been administered as of September 1, with no dose-limiting toxicities reported and no treatment-emergent adverse events leading to treatment discontinuation, including at the highest evaluated dose of 4.8 mg/kg. Exploratory RNA-sequencing analysis identified treatment-associated immune effects that the company said support the observed clinical activity, although the small-sample biomarker findings require confirmation in larger studies. TransCode is evaluating dose-expansion strategies and plans to continue assessing safety, pharmacokinetics, pharmacodynamics, and antitumor activity. To view the full press release, visit https://ibn.fm/mIBZR.
TransCode Therapeutics is a clinical-stage company pioneering immuno-oncology and RNA therapeutic treatments for high-risk and advanced cancers. Its lead candidate, TTX-MC138, targets metastatic tumors overexpressing microRNA-10b, a well-documented biomarker of metastasis. The company also has a portfolio of first-in-class therapeutic candidates designed to mobilize the immune system against cancer cells. The latest news and updates relating to RNAZ are available in the company’s newsroom at https://ibn.fm/RNAZ. This update was distributed by BioMedWire, a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences, which is part of the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode's TTX-MC138 Shows 71% Disease Control in Phase 1a
